Background. Kaposi sarcoma (KS) is a complication of KS-associated herpesvirus (KSHV) infection. Other oncogenic viral infections and malignancies are associated with certain HLA alleles and their natural killer (NK) cell immunoglobulin-like receptor (KIR) ligands. We tested whether HLA-KIR influences the risk of KSHV infection or KS.
The gene encoding human leukocyte antigen (HLA) and related genes are centrally involved in the immunological response to infectious diseases and thus would be expected to affect the risk of developing KSHV infection or KS. Only tenuous support for this hypothesis has been reported. In a meta-analysis of 12 publications from 1981-1994, Ioannidis et al concluded that the risk of AIDS-associated KS was significantly decreased with HLA-DR3 and significantly increased with HLA-B*35 and Cw4, 2 loci that are in strong linkage disequilibrium [6] . They noted, however, that these studies had serious deficiencies, ranging from exceedingly small sample size to uncontrolled confounding by strong HLA associations with AIDS, especially for HLA-B*35. A 2005 analysis in the Multicenter AIDS Cohort Study, which matched 147 AIDSassociated KS cases to 147 HIV-seropositive KSHV-seropositive controls, only found associations with HLA-B*27, which is also associated with slower HIV progression, and with 1 HLA class II haplotype (DRB1*13:02-DQB1*06:04) [7] . Unfortunately, that latter study included no KSHV-seronegative controls and did not examine HLA-A or HLA-C alleles. Previous studies of HLA associations with classic KS and with non-AIDS-associated KS in Africa have been predominantly null [8] [9] [10] [11] [12] [13] [14] , but they have been seriously underpowered, with only 62 cases in the largest study.
Because the innate immune system plays a key role in the response to viral infections and cancer, our understanding of KSHV disease pathogenesis may be advanced by considering interactions between HLA and killer cell immunoglobulin-like receptor (KIR) ligand pairs. Positioned on the surface of natural killer (NK) cells, KIRs are a polymorphic family of receptors that regulate NK-mediated cytotoxicity when ligated to requisite HLA class I molecules. Three studies have reported significant associations of KIR3DS1 (activating), KIR3DL1 (inhibitory), or HLA-C group alleles for cervical cancer or precancer, which results from persistent infection with oncogenic types of human papillomavirus (HPV) [15] [16] [17] . More recently, Guerini et al studied KIR and HLA class I ligand pairs in 32 northern Italian persons with classic KS and 51 controls, of whom 18 were KSHV seropositive [18] . They found that activating KIR/HLA genotypes, specifically KIR3DS1, KIR2DS1, and KIR2DS1+HLA-C group 2, were significantly more frequent in persons with classic KS [18] .
To further test the hypothesis that HLA and KIR influence the risk of KSHV seropositivity or KS, we compared HLA class I and KIR/HLA ligand frequencies in a 2-phase study that included a 250 persons with classic KS, 280 KSHV-seropositive controls, and 576 KSHV-seronegative controls in Italy.
METHODS

Subjects
As described previously in depth [3, 4] , individuals with histologically confirmed classic KS who were seronegative for HIV and had no history of transplantation were recruited in Italy from the provinces of Lazio (including Rome), Campania (including Naples), and the entire island of Sicily. Contemporaneous controls with a similar age and sex distribution were recruited from the rosters of primary care physicians in the same geographic areas. KSHV seropositivity was determined by an immunofluorescence assay (IFA), performed at a 1:120 dilution with uninduced BCBL-1 cells, plus an enzyme immunoassay with recombinant K8.1 structural glycoprotein at a 1:20 plasma dilution.
Subjects were considered KSHV seropositive if they had uninduced IFA positivity or a K8.1 optical density of >1.2. KSHVseronegative individuals had uninduced IFA negativity plus a K8.1 optical density of ≤1.2. Twenty-four controls with missing or ambiguous KSHV serologic findings were included in the current study for comparisons of persons with classic KS to all controls. The current analysis was composed of discovery (phase 1) and validation (phase 2) cohorts (Table 1) .
HLA Class I Genotyping
High-resolution genotyping for HLA class I loci was performed by polymerase chain reaction-sequence-based typing, as recommended by the 13th International Histocompatibility Workshop (available at: http://www.ihwg.org/tmanual/TMcon tents. htm). HLA sequences were analyzed using the ASSIGN software (Conexio Genomics).
KIR Genotyping
KIR genotyping for the presence or absence of each KIR gene was conducted by polymerase chain reaction with sequencespecific priming as described previously [19] , with some modifications. PCR was conducted using SYBR Green Master Mix with Platinum Taq (Life Technologies). The presence and absence of specific PCR products was detected by melting curve analysis on the 7900 Real-Time PCR System (Applied Biosystems).
Statistical Analyses
First, to assess associations with KSHV seroprevalence, KSHVseropositive controls and KSHV-seronegative controls were compared on their HLA allele, KIR gene, and KIR ligand frequencies. Second, to assess associations with disease, frequencies of these genotypes among individuals with classic KS were compared to those among controls. Patients with classic KS were compared to controls, with and without stratification on KSHV serostatus. The frequency of the inhibitory KIR2DL1 and KIR2DL2/3 alleles (KIR2DL2 and KIR2DL3 are alleles of the same locus, and the gene that encodes these receptors is present on virtually all haplotypes), which interact with HLA-C group 2 and -C group 1 alleles, respectively, is nearly 100%. Thus, analysis was restricted to assessment of variation in their ligand frequency. Unlike several of the inhibitory KIRs, activating KIRs are present on only a fraction of KIR haplotypes, and therefore activating KIR with known or putative HLA ligands were interrogated together. For all analyses, logistic regression was used to estimate odds ratios (ORs), adjusted for age and sex, and corresponding 95% confidence intervals (CIs). The significant associations identified in phase 1 were tested in phase 2, followed by analysis of both phases combined.
RESULTS
HLA alleles and KIR genes were successfully determined in 1130 participants, including 250 persons with classic KS, 280 KSHV-seropositive controls, 576 KSHV-seronegative controls, and 24 KSHV-seroindeterminant controls (Table 1 ). There were 793 men and 337 women, with a mean age of 72 years (range, 28-94 years). Case and control groups did not differ by phase of the study, although phase 1 was larger than phase 2 (689 vs 441).
KSHV Seroprevalence
Among the controls, we compared KSHV-seropositive individuals to KSHV-seronegative individuals for possible associations of KSHV seroprevalence with each HLA-A, HLA-B, and HLA-C allele and KIR gene in phase 1. Four (HLA-A*30:02, HLA-B*15:01, and HLA-B*35:02 and KIR2DL3) were nominally associated with seroprevalence, but none of these findings were replicated in phase 2 (Supplementary Table 1 ). Based on this, the KSHV-seropositive and KSHV-seronegative control groups were pooled for comparison to persons with classic KS with regard to single HLA alleles and KIR genes.
Risk of Classic KS
Two HLA alleles were reproducibly associated with classic KS, compared with all controls in phase 1 and 2 ( Table 2) . Persons with classic KS had a reduced frequency of A*11:01 in phase 1 (adjusted OR, 0.4; 95% CI, .2-.9), which was replicated in phase 2 (adjusted OR, 0.4; 95% CI, .2-.8). Conversely, there was a significantly increased risk of classic KS for participants carrying C*07:01 in phase 1 (adjusted OR, 1.5; 95% CI, 1.0-2.2), which was replicated in phase 2 (adjusted OR, 1.7; 95% CI, 1.1-2.6). None of the other HLA alleles and none of the KIR genes was reproducibly associated with classic KS (see Supplementary  Tables 2-6 for results of analyses performed in phase 1).
KIR Ligands With KSHV Seroprevalence
In contrast to single HLA alleles and KIR genes, joint classification of participants according to their HLA-B and -C KIR ligand motifs revealed associations with KSHV seroprevalence and classic KS (Table 3 and Figure 1 ). With the compound genotype HLA-B Bw4-80I plus KIR3DS1, KSHV seroprevalence was significantly reduced in phase 1 (adjusted OR, 0.6; 95% CI, .3-.9), with an identical point estimate but nonsignificant 95% CI in phase 2 (adjusted OR, 0.6; 95% CI, .3-1.2). With both phases combined, the KSHV seroprevalence was reduced with HLA-B Bw4-80I plus KIR3DS1 (adjusted OR, 0.6; 95% CI, .4-.9). Similarly, homozygosity for HLA-C group 1 (the ligand for KIR2DL2/3) was associated with reduced seroprevalence, which was nonsignificant in phase 1 (adjusted OR, 0.7; 95% CI, .4-1.1), but reached significance in phase 2 (adjusted OR, 0.5; 95% CI, .3-1.0). With both phases combined, HLA-C group 1 homozygosity was associated with a lower KSHV seroprevalence (adjusted OR, 0.6; 95% CI, .4-.9). Excluding C*07:01 (a constituent of C group 1) had little effect (Table 3) .
KIR Ligands With Classic KS
Because the risk of KSHV seroprevalence was associated with KIR ligands, persons with classic KS were compared only to the KSHV-seropositive controls, thereby evaluating the risk of classic KS conditional on KSHV infection. In this analysis, classic KS was significantly increased with the compound genotype HLA-B Bw4-80I plus KIR3DS1 in phase 1 (adjusted OR, 2.1; 95% CI, 1.2-3.8), with an identical point estimate but nonsignificant CI in phase 2 (adjusted OR, 2.1; 95% CI, .9-4.8).
With both phases combined, classic KS was increased with HLA-B Bw4-80I plus KIR3DS1 (adjusted OR, 2.1; 95% CI, 1.3-3.4). These associations suggest that this compound genotype confers protection against KSHV infection but that, among those who do become infected, there is an increased risk of developing classic KS.
A similar pattern was seen with HLA-C group 1 homozygosity, for which the risk of classic KS was significantly increased in phase 1 (adjusted OR, 1.8; 95% CI, 1.1-3.1), phase 2 (adjusted OR, 1.9; 95% CI, 1.0-4.0), and both phases combined (adjusted OR, 1.8; 95% CI, 1.2-2.7). The risk of classic KS with C group 1 homozygosity was higher with exclusion of C*07:01 (adjusted OR, 2.7; 95% CI, 1.5-4.9; Table 3 ), an allele that is a constituent of C group 1 and that itself was associated with classic KS C1 denotes HLA-C*01, HLA-C*03, HLA-C*07, and HLA-C*08, and C2 denotes HLA-C*02, HLA-C*04, HLA-C*05, and HLA-C*06 [20, 21] . HLA-B Bw4 80I denotes HLA-B*27:02, HLA-B*38:01, HLA-B*49:01, HLA-B*51, HLA-B*57, and HLA-B*58 [22, 23] .
Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; NS, not significant. a Adjusted for HLA-C*07:01.
( Table 2 ). This pattern of a given genotype protecting against infection but increasing the risk of disease among those who do become infected was thus consistent for HLA-C group 1 homozygosity and HLA-B Bw4-80I plus KIR3DS1.
DISCUSSION
This is the first comprehensive study to assess the role of HLA and KIR on the risk of KSHV seroprevalence and classic KS. There were several major findings. First, we observed significant opposing effects of activating KIR/HLA combinations on seroprevalence and the risk of classic KS. Second, seroprevalence had no consistently significant association with any individual HLA allele or KIR gene. Third, in contrast to seroprevalence, the risk of classic KS was significantly and reproducibly associated with 2 HLA alleles when compared to combined control groups. In both phases of our study, the risk of classic KS was significantly reduced in people with A*11:01, and it was increased for those with C*07:01. Whether or not A*11:01 and C*07:01 have similar associations in African KS remains to be determined. African KS differs from the Mediterranean form in terms of epidemiologic characteristics and clinical outcomes, and there are significant differences in HLA allele frequencies in these populations. Thus, it is unlikely that this will be the case. Intriguingly, A*11:01 is well known to be associated with decreased risk for nasopharyngeal carcinoma [24] [25] [26] . Nasopharyngeal carcinoma is strongly associated with Epstein-Barr virus infection, which, like KSHV, is a γ-herpes virus. This implies that A*11:01 may present herpesvirus-related antigenic epitopes to cytotoxic T lymphocytes, resulting in effective control of the virus in the lytic phase. Functional cytotoxic T-lymphocyte assays to confirm this will need to be performed. There is clinical evidence to suggest that lytic KSHV replication is important for progression to KS. In a clinical trial [27] , patients with AIDS and cytomegalovirus retinitis were randomly assigned to one of 3 treatment arms: intravenous ganciclovir alone, oral plus ocularimplant ganciclovir, or placebo plus ocular-implant ganciclovir. Compared with oral placebo, the risk of AIDS-associated KS was reduced 75% with oral ganciclovir and 93% with intravenous ganciclovir [27] , highly significant effects that the authors attribute to the blockage of lytic KSHV replication by ganciclovir.
The significant opposing effects of activating KIR/HLA combinations on seroprevalence versus classic KS merit special attention. HLA-C group 1 alleles, which serve as ligands for the inhibitory KIR2DL2/3, were significantly associated with protection against KSHV seroprevalence. This KIR/HLA combination has a relatively weak NK cell inhibitory potential relative to that of KIR2DL1 in the presence of its HLA-C group 2 ligand [28] , which is strongly inhibitory. On the other hand, C group 1 alleles were associated with an increased risk of classic KS among KSHV-infected subjects. Likewise, the combination of the activating KIR3DS1 with HLA-B Bw4-80I was protective against seroprevalence but associated with an increased risk of classic KS (Table 3 and Figure 1 ). Our findings corroborate the classic KS association with activating KIR reported by Guerini et al [18] and add the novel association with KSHV seroprevalence. We hypothesize that strong NK cell activation protects against seropositivity but is a risk factor for classic KS after KSHV infection (Figure 2 ), perhaps because of the known association of KS with inflammation [29] . These findings expand previously reported and remarkably similar HLA-KIR associations with HPV-induced cervical neoplasia [16, 17] and with Epstein-Barr virus-related nasopharyngeal carcinoma [30] , in which the risk of the neoplasm was increased in the presence of activating KIR/HLA combinations. Opposing effects of HLA-C group 1 (A) and KIR3DS1/Bw4-80I (B) on the risk of Kaposi sarcoma (KS)-associated herpesvirus (KSHV) infection and classic KS after KSHV infection. A, HLA-C group 1 alleles, which serve as ligands for the inhibitory KIR2DL2/3, were significantly associated with protection against KSHV infection. This KIR/ HLA combination has a relatively weak natural killer (NK) cell inhibitory potential relative to KIR2DL1 in the presence of its HLA-C group 2 ligand, which is strongly inhibitory. On the other hand, C group 1 alleles were associated with an increased risk of classic KS among KSHV infected subjects. B, The combination of the activating KIR3DS1 with HLA-B Bw4-80I was protective against infection but associated with an increased risk of classic KS. Abbreviation: OR, odds ratio.
The modulation of NK cell-mediated inflammation by KIR may be beneficial against infectious agents but detrimental in controlling neoplasia. More specifically, emerging data suggest that KIR may help to control certain viruses, including HIV and hepatitis C virus, while also increasing the risk for some inflammation-mediated conditions, including cancers [31] [32] [33] . A key aspect of KS is its association with inflammation. Indeed, it is well known that there is a propensity for the development of KS lesions at local sites of inflammation, such as herpes zoster skin lesions [34] and foci of trauma (Koebner phenomenon) [35] . Furthermore, several viral genes encode proteins that contribute to a proinflammatory environment, including viral interleukin 6, viral CC chemokine homologs, and viral interferon regulatory factor [36] . Matthews et al have recently demonstrated that NK cells activated by cytokines successfully kill KSHV-infected fibroblasts [37] . However, multiple perturbations of systemic immunity are a hallmark of KS, and KS is exacerbated by administration of exogenous interferon γ [38, 39] . The role of NK cells and KIR in the development of KS has not been studied in depth. Further functional studies are warranted to clarify the findings described herein and to understand their role in the development of KS.
The strengths of this study include analysis of a well-defined population [4, 40] , a 2-phase design to validate associations, stratified assessment of KSHV serostatus and classic KS disease, stateof-the-art HLA and KIR genotyping, avoidance of confounding by HIV, and substantial size (13-fold larger than the only prior study of HLA-KIR and classic KS [18] ). In summary, this study uncovered reproducible associations of HLA-A*11:01 and HLA-C*07:01 with the risk of classic KS. It also uncovered countervailing HLA-KIR ligand associations with KSHV serostatus and classic KS. These findings suggest that KIR-mediated NK cytotoxicity may retard initial KSHV infection. After infection, however, it may, along with other factors, enhance KSHV dissemination to lymphatic endothelial cells and progression to KS.
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